Shots:

• The P-II trial evaluating patritumab deruxtecan (5.6mg/kg) in a ratio (1:1) in patients with EGFR-mutated LA or metastatic NSCLC following disease progression with an EGFR TKI and Pt-based CT in Asia, EU, North America & Oceania
• The results showed clinically meaningful & durable responses, confirmed ORR (29.8%), 1 CR, PR (66) & 99 cases of SD, m-DoR of 6.4mos. & DCR (73.8%), m-PFS was 5.5mos. & m-OS was 11.9mos. Efficacy outcomes were consistent across subgroups incl. a subset of 209 patients prior treated with a third-generation EGFR TKI and Pt-based CT
• The safety profile was consistent with prior clinical trials with a low rate (7.1%) of treatment discontinuation due to TEAEs, grade ≥3 (64.9%). The results were published in the Journal of Clinical Oncology

Ref: Businesswire | Image: Daiichi Sankyo

Related news:- Daiichi Sankyo Initiates P-II Study of Patritumab Deruxtecan in Patients with EGFR-Mutated NSCLC

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com